Nov 17, 2017 - Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Nov 17, 2017 - Gilead has adopted the right strategy in CAR-T. Egalet soars almost 40%. Aerie launches mid-stage study.
Nov 17, 2017 - Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
Nov 16, 2017 - The annual GlaxoSmithKline IMPACT Awards have seen another set of 10 local nonprofits bank $40,000 each for their contributions to health in the Triangle.
“Health is about so much more than what happens in the doctor’s office,” stated Jamey Millar, senior vice president of GSK's Managed Markets & Government Affairs. “All of the community issues that our GSK IMPACT Award Winners address have a meaningful impact on health outcomes for individuals and families in the Triangle.”
Nov 15, 2017 - Airbus has scored the biggest deal in its history, negotiating to sell 430 A320neos - valued at nearly $50B - to investment fund Indigo Partners. The pact gives Airbus (OTCPK:EADSY) the upper hand at
Nov 15, 2017 - AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.
Nov 14, 2017 - GSK, the top safer dividend healthcare stock, with a 32.1% net gain was 3x Pfizer's 10.4% second-place effort, and 10x JNJ's eighth-place gains as per analyst targets.21 of 77 healthcare sector stocks
Nov 14, 2017 - Kahn Brothers Reduces Positions in Straight Path, New York Times, Hologic, Several Others, Stocks: STRP,NYT,HOLX,SEB,C,GSK,MBI, Kahn Brothers, release date:Nov 14, 2017
Nov 14, 2017 - GSK regained top dog by net gains, while TEVJF led again by yield as calculated 11/13/17.The Healthcare sector is composed of ten component industries. The top 50 firms selected by yield for this writ
Nov 14, 2017 - Heron Therapeutics now has two approved products.Theravance has submitted revefenacin NDA.Nektar shares have gained more than 50% since last week.